Skip to content

AP Laboratory Solutions

Leading anatomic pathology institutions use AISight® Dx1 as a digital pathology image management system to support primary diagnosis and modern laboratory workflows.

PathAI receives FDA clearance for AISight® Dx

A complete, cloud‑native solution that centralizes case and image management on an intelligent platform.

PathAI has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight Dx—PathAI’s digital pathology image management system—for use in primary diagnosis in clinical settings.

Read the press release

AISight® Dx Digital Pathology Platform

Interpret, share, and manage whole slide images of all sizes — from individual labs to large hospital networks

AISight Dx is a cloud-native digital pathology platform that streamlines diagnostic workflows and enables precision collaboration. With end-to-end automation, intelligent case routing, and robust image management tools, it supports accurate, efficient diagnoses across locations. Compliant with enterprise standards, AISight ensures PHI security and quality control for labs, hospitals, and academic centers.

Request a demo

AISight Dx Overview

AISight Dx is a cloud-native digital pathology platform purpose-built to modernize anatomic pathology workflows. With intelligent case management, high-performance slide review, and seamless collaboration, AISight Dx helps labs boost efficiency, improve diagnostic consistency, and support high-quality patient care. FDA-cleared for use with Leica Aperio® GT 450 DX, Hamamatsu NanoZoomer® S360MD, Roche VENTANA® DP200 and DP600 slide scanners, AISight Dx offers seamless interoperability, supporting organizations of any size across multiple sites.

Learn how our FDA‑cleared platform can help modern labs streamline workflows and foster precision collaboration.

IVD Case Viewer

Seamless Collaboration & Consults

AISight Dx brings seamless, real-time collaboration to digital pathology—enabling synchronized and asynchronous slide review, expert consults, and education in a secure, user-centric workspace. With a share-ready IMS and flexible access from anywhere, AISight Dx empowers the right specialists to connect and collaborate—when and where it matters most.

Intelligent Case Management

The Intelligent Caselist dashboard offers filterable workload charts, persistent search and filter settings across pages and sessions, and lets supervisors seamlessly assign or reassign cases to specific pathologist, allowing them to easily understand and navigate their daily worklist.

Screenshot 2026-06-01 at 2.10.04 PM

High-Performance Case Review

A high-performance slide viewer enables seamless review of whole slide images, offering a suite of tools about customizations to support an ideal workflow for each pathologist.

Enhanced Annotation Features

A robust set of tools including lines, arrows, shapes, and freehand drawing, combined with threaded comments and user tagging to support asynchronous slide review. Users can tag colleagues in specific comments, which triggers an immediate notification and brings them directly to the relevant annotation. This enables fast and focused collaboration across teams.

AISight Consults

One platform. Streamlined consult workflow management.

AISight® Dx IMS platform supports consult workflow capabilities through the AISight Consults workflow, enabling institutions to send, receive, review, and report on consult cases within a unified IMS experience, without adding a separate consult tool. 

Learn more
Untitled design (13)

Explore What AISight Dx Can Do for Your Lab

Schedule a Demo

Explore how AISight® Dx streamlines digital pathology workflows with efficient case review, collaboration, and operational visibility.

Experience AISight Dx
guys-office-screen (1)

Connect with our team

To learn more about how AISight Dx at

1AISight® Dx is FDA-cleared for primary diagnosis in the US with the Hamamatsu NanoZoomer® S360MD, Leica Aperio® GT 450 DX, Roche VENTANA® DP200 and DP600 slide scanners and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland.